COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

bioRxiv posts many COVID19-related papers. A reminder: they have not been formally peer-reviewed and should not guide health-related behavior or be reported in the press as conclusive.

29,117 Articles (21,576 medRxiv, 7,541 bioRxiv)

Most recent first Previous |  Page 144: Articles 1431-1440  | Next

Distinct COVID-19 vaccine combinations result in divergent immune responses
Zaeck, L. M., Tan, N. H., Rietdijk, W. J. R., Geers, D., Sablerolles, R. S. G., Bogers, S., van Dijk, L. L. A., Gommers, L., van Leeuwen, L. P. M., Rugebregt, S., Goorhuis, A., Postma, D. F., Visser, L. G., Dalm, V. A. S. H., Lafeber, M., Kootstra, N. A., Huckriede, A. L. W., Haagmans, B. L., van Baarle, D., Koopmans, M. P. G., van der Kuy, P. H. M., GeurtsvanKessel, C. H., de Vries, R. D., SWITCH-ON Research Group
10.1101/2023.08.25.23294606 — Posted: 2023-08-25
Modelling the Interplay between Responsive Individual Vaccination Decisions and the Spread of SARS-CoV-2
Wallrafen-Sam, K., Garcia Quesada, M., Lopman, B. A., Jenness, S. M.
10.1101/2023.08.24.23294588 — Posted: 2023-08-25
An After-Action Review of COVID-19 Cases and Mitigation Measures at US Mission India, March 2020-July 2021
Singh, J., Yadav, R., Robinson, S., Vanelli, M., Nyendak, M., Desai, M.
10.1101/2023.08.24.23294557 — Posted: 2023-08-25
Protection conferred by COVID-19 vaccination, prior SARS-CoV-2 infection, or hybrid immunity against Omicron-associated severe outcomes among community-dwelling adults
Lee, N., Nguyen, L., Austin, P. C., Brown, K. A., Grewal, R., Buchan, S. A., Nasreen, S., Gubbay, J., Schwartz, K. L., Tadrous, M., Wilson, K., Wilson, S. E., Kwong, J. C.
10.1101/2023.08.24.23294503 — Posted: 2023-08-25
Risk factors for SARS-Cov-2 infection at a United Kingdom electricity-generating company: a test-negative design case-control study
Rutter, C. E., Van Tongeren, M. J., Fletcher, T., Rhodes, S. E., Chen, Y., Hall, I., Warren, N., Pearce, N.
10.1101/2023.08.25.23294609 — Posted: 2023-08-25
RCT-based Social Return on Investment (SROI) of a home exercise programme for people with early dementia comparing in-person and blended delivery before and during the COVID-19 pandemic
Doungsong, K., Hartfiel, N., Gladman, J., Harwood, R. H., Edwards, R. T.
10.1101/2023.08.25.23294408 — Posted: 2023-08-25
Efficient Sequence Embedding For SARS-CoV-2 Variants Classification
Ali, S., Sardar, U., Khan, I., Patterson, M.
10.1101/2023.08.24.554650 — Posted: 2023-08-25
Mucosal antibody responses to SARS-CoV-2 booster vaccination and breakthrough infection
Bhavsar, D., Singh, G., Sano, K., Gleason, C., Srivastava, K., Carreno, J. M., Simon, V., Krammer, F.
10.1101/2023.08.24.554732 — Posted: 2023-08-25
Antibody Neutralization of Emerging SARS-CoV-2: EG.5.1 and XBC.1.6
Wang, Q., Guo, Y., Zhang, R. M., Ho, J., Mohri, H., Valdez, R., Manthei, D. M., Gordon, A., Liu, L., Ho, D. D.
10.1101/2023.08.21.553968 — Posted: 2023-08-25
Gender differences in submission behavior exacerbate publication disparities in elite journals
Basson, I., Ni, C., Badia, G., Tufenkji, N., Sugimoto, C. R., Lariviere, V.
10.1101/2023.08.21.554192 — Posted: 2023-08-25

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).